Clinical Trial Update: MK-8189 Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017) [Phase 1]

View source ↗

Summary

Phase 1 trial MK-8189 in adults with Alzheimer's disease evaluated safety and tolerability, including participants with or without agitation, aggression, or psy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• MK-8189

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED | Results posted: 2024-09-25